Investigators of studies of n = 1: Pioneers or kamikazes?

N. Bonetti; Jürg H. Beer

doi:10.4414/smw.2015.14070

Viewpoint

Vol. 145 No. 0304 (2015)

Investigators of studies of n = 1: Pioneers or kamikazes?

N. Bonetti
Jürg H. Beer

DOI: https://doi.org/10.4414/smw.2015.14070
Cite this as:: Swiss Med Wkly. 2015;145:w14070
Published: 11.01.2015

References

Massobrio L, Rosa GM, Montecucco F, Valbusa A. Treatment with apixaban in a patient with recent chronic subdural haematoma: a case report. Swiss Med Wkly. 2015;145:w14048. http://www.smw.ch/content/smw-2015-14048
Bleuler E. Das autistisch-undisziplinierte Denken in der Medizin und seine Überwindung. 1919.
Torihashi K, Sadamasa N, Yoshida K, Narumi O, Chin M, Yamagata S. Independent predictors for recurrence of chronic subdural hematoma: a review of 343 consecutive surgical cases. Neurosurgery. 2008;63(6):1125.
Poli D, Anonucci E, Dentali F, Erba N, Testa S, Palareti G, et al. Recurrence of ICH after resumption of anticoagulation with VK antagonists CHIRONE Study. Neurology. 2014;82(12):1020–6
Lindvall P, Koskinen LO. Anticoagulants and antiplatelet agents and the risk of development and recurrence of chronic subdural haematomas. J Clin Neurosci. 2009;16(10):1287.
Forster MT, MathéAK, Senft C, Scharrer I, Seifert V, Gerlach. The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma. J Clin Neurosci. 2010;17(8):975.
Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
Reilly PA, Lehr T, Haertter S, Connolly SJ, Wallentin L, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial. J Am Coll Cardiol. 2014;63(4):321–8
Roldan V, Marin F, Fernandez H, Manzano Fernandez S, Lip GY. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real world” population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013;143(1):179–84
Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation and risk stratification for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. doi: 10.1136/bmj.d124
Carlsen JG, Cortnum S, Sørensen JC. Recurrence of chronic subdural haematomata with and without post-operative drainage. Br J Neurosurg. 2011;25(3):388.
Santarius T, Qureshi HU, Sivakumaran R, Kirkpatrick PJ, Kirollos RW, Hutchinson PJ. The role of external drains and peritoneal conduits in the treatment of recurrent chronic subdural hematoma. World Neurosurg. 2010;73(6):747.
Yu GJ, Han CZ, Zhang M, Zhuang HT, Jiang YG. Prolonged drainage reduces the recurrence of chronic subdural hematoma. Br J Neurosurg. 2009;23(6):606.
Wintzen AR, Tijssen JGP. Subdural Hematoma and Oral Anticoagulation Therapy. ANN Neurol. 29:69–72
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in patients in non valvular atrial fibrillation. N Engl J Med. 2011;365: 883–91.
Nagarkani R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131–6.
Flaker G, Lopes RD, Al-Kathib SM, Granger CB, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke an Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082–7. doi
Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Breithardt G. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61(19):1998–2006.
Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol. 2003;123: 676–82.
Sie P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, et al. Surgery and invasive procedures in patients on long term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the working group on perioperative Haemostasis and the French study group on thrombosis and haemostasis. Arch Cardiovas Dis. 2011;104:669–76.
Conolly S, Eikelboom J, Joyner C, Diener H, Hart R, Yusuf S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17.

How to Cite

1.

Bonetti N, Beer JH. Investigators of studies of n = 1: Pioneers or kamikazes?. Swiss Med Wkly [Internet]. 2015 Jan. 11 [cited 2024 Nov. 22];145(0304):w14070. Available from: https://smw.ch/index.php/smw/article/view/1973

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Most read articles by the same author(s)

Micha T. Maeder, Tabea König, Sanja Bogdanovic, Irene Schneider, Werner Eugster, Peter Ammann, Marius König, Jürg H. Beer, Hans Rickli, Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation – real-life data from a survey in Eastern Switzerland , Swiss Medical Weekly: Vol. 147 No. 3940 (2017)
Maria-Pia Mahler, Karl Züger, Kurt Kaspar, Andreas Haefeli, Walter Jenni, Tobias Leniger, Jürg H. Beer, A cost analysis of the first year after stroke - early triage and inpatient rehabilitation may reduce long term costs , Swiss Medical Weekly: Vol. 138 No. 3132 (2008)
Jürg H. Beer, Vitamin K antagonists are hard to beat by the price – are they? Some answers, new questions and the GPs’ dilemma , Swiss Medical Weekly: Vol. 143 No. 0102 (2013)

[1] Massobrio L, Rosa GM, Montecucco F, Valbusa A. Treatment with apixaban in a patient with recent chronic subdural haematoma: a case report. Swiss Med Wkly. 2015;145:w14048. http://www.smw.ch/content/smw-2015-14048

[2] Bleuler E. Das autistisch-undisziplinierte Denken in der Medizin und seine Überwindung. 1919.

[3] Torihashi K, Sadamasa N, Yoshida K, Narumi O, Chin M, Yamagata S. Independent predictors for recurrence of chronic subdural hematoma: a review of 343 consecutive surgical cases. Neurosurgery. 2008;63(6):1125.

[4] Poli D, Anonucci E, Dentali F, Erba N, Testa S, Palareti G, et al. Recurrence of ICH after resumption of anticoagulation with VK antagonists CHIRONE Study. Neurology. 2014;82(12):1020–6

[5] Lindvall P, Koskinen LO. Anticoagulants and antiplatelet agents and the risk of development and recurrence of chronic subdural haematomas. J Clin Neurosci. 2009;16(10):1287.

[6] Forster MT, MathéAK, Senft C, Scharrer I, Seifert V, Gerlach. The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma. J Clin Neurosci. 2010;17(8):975.

[7] Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

[8] Reilly PA, Lehr T, Haertter S, Connolly SJ, Wallentin L, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial. J Am Coll Cardiol. 2014;63(4):321–8

[9] Roldan V, Marin F, Fernandez H, Manzano Fernandez S, Lip GY. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real world” population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013;143(1):179–84

[10] Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation and risk stratification for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. doi: 10.1136/bmj.d124

[11] Carlsen JG, Cortnum S, Sørensen JC. Recurrence of chronic subdural haematomata with and without post-operative drainage. Br J Neurosurg. 2011;25(3):388.

[12] Santarius T, Qureshi HU, Sivakumaran R, Kirkpatrick PJ, Kirollos RW, Hutchinson PJ. The role of external drains and peritoneal conduits in the treatment of recurrent chronic subdural hematoma. World Neurosurg. 2010;73(6):747.

[13] Yu GJ, Han CZ, Zhang M, Zhuang HT, Jiang YG. Prolonged drainage reduces the recurrence of chronic subdural hematoma. Br J Neurosurg. 2009;23(6):606.

[14] Wintzen AR, Tijssen JGP. Subdural Hematoma and Oral Anticoagulation Therapy. ANN Neurol. 29:69–72

[15] Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in patients in non valvular atrial fibrillation. N Engl J Med. 2011;365: 883–91.

[16] Nagarkani R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131–6.

[17] Flaker G, Lopes RD, Al-Kathib SM, Granger CB, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke an Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082–7. doi

[18] Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Breithardt G. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61(19):1998–2006.

[19] Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol. 2003;123: 676–82.

[20] Sie P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, et al. Surgery and invasive procedures in patients on long term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the working group on perioperative Haemostasis and the French study group on thrombosis and haemostasis. Arch Cardiovas Dis. 2011;104:669–76.

[21] Conolly S, Eikelboom J, Joyner C, Diener H, Hart R, Yusuf S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17.